4-(2-(5-6-7-8-tetrahydro-5-5-8-8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic-acid and Prurigo

A woman had symmetrically distributed pruritic nodules for more than 40 years. Microscopically they were characterized by proliferation of nonmyelinated nerve fibers (Pautrier's neuroma) and a total absence of epidermal involvement. Anetoderma developed at the site of former nodules. Her condition responded favorably to repeated retinoid therapy with regression of nodules in those sites in which retinoid dermatitis had developed.

Topics: Aged; Benzoates; Female; Humans; Neuroma; Prurigo; Retinoids; Skin Diseases; Skin Neoplasms

Ro 13-7410 was given to 29 patients (a total of 38 treatment courses) for 7.5 weeks (range 4-23). This compound is one of the most potent retinoids ever synthetized and has the highest affinity to human skin cellular retinoic-acid-binding protein. At therapeutically active doses, it did not induce the commonly seen mucocutaneous signs of retinoid toxicity such as scaling and cheilitis; over 0.5 microgram/kg body weight/day, it very frequently induced an eczematous retinoid dermatitis. This pilot study provides some indications on what appears to be in several aspects a drug quite distinct from retinoids previously used in humans.

Topics: Adult; Aged; Benzoates; Dermatitis; Female; Humans; Male; Middle Aged; Pilot Projects; Prurigo; Psoriasis; Retinoids; Skin Diseases